EGFR and non-small cell lung carcinoma: Comparatively, our previous analysis using archival tissue samples showed that a subpopulation of NSCLC tumors expressed elevated levels of heregulin following development of gefitinib resistance, versus those observed prior to EGFR-TKI therapy [22].